🔗 Share this article World Health Organization Issues Concern Over Critical Shortage of Obesity Injections Less than one in 10 patients eligible to benefit from obesity jabs like Wegovy have access to them, caution the World Health Organization as it releases its first guidance on the medications. With more than one billion individuals worldwide currently obese, it is advocating for more widespread and fairer access to GLP-1 medication. According to projections, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken. "The new guidelines acknowledges that excess weight is a lifelong illness that can be managed with holistic and lifelong care," stated WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, limited production capacity, and logistical bottlenecks are key barriers to universal access to the treatments that can assist patients in reducing significant weight, notes the body. GLP-1 Therapy Supply Crisis Despite the current most favorable outlook, the production of these medications might only reach approximately 100 million people – less than 10% of eligible patients, as stated by the health organization. The guideline encourages governments and firms to widen access, via measures such as voluntary licensing. Exclusive production rights on semaglutide – the main ingredient of a leading brand – is scheduled to end in several nations in 2026. The Way Weight-Loss Jabs Function The injections replicate a biological compound to reduce digestion speed, suppress the appetite and enhance feelings of fullness so people consume fewer calories. People commonly start to lose weight within a few weeks of beginning the weekly injections. Evidence suggests people may put most of the weight back on a year later of halting the drug, because their usual food cravings resume. To be carrying excess weight increases your likelihood for contracting diseases, like type 2 diabetes, cardiovascular issues, brain attack, and certain cancers. Obesity impacts individuals in countries worldwide and was associated with 3.7 million deaths worldwide in 2024, per the WHO.
Less than one in 10 patients eligible to benefit from obesity jabs like Wegovy have access to them, caution the World Health Organization as it releases its first guidance on the medications. With more than one billion individuals worldwide currently obese, it is advocating for more widespread and fairer access to GLP-1 medication. According to projections, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken. "The new guidelines acknowledges that excess weight is a lifelong illness that can be managed with holistic and lifelong care," stated WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, limited production capacity, and logistical bottlenecks are key barriers to universal access to the treatments that can assist patients in reducing significant weight, notes the body. GLP-1 Therapy Supply Crisis Despite the current most favorable outlook, the production of these medications might only reach approximately 100 million people – less than 10% of eligible patients, as stated by the health organization. The guideline encourages governments and firms to widen access, via measures such as voluntary licensing. Exclusive production rights on semaglutide – the main ingredient of a leading brand – is scheduled to end in several nations in 2026. The Way Weight-Loss Jabs Function The injections replicate a biological compound to reduce digestion speed, suppress the appetite and enhance feelings of fullness so people consume fewer calories. People commonly start to lose weight within a few weeks of beginning the weekly injections. Evidence suggests people may put most of the weight back on a year later of halting the drug, because their usual food cravings resume. To be carrying excess weight increases your likelihood for contracting diseases, like type 2 diabetes, cardiovascular issues, brain attack, and certain cancers. Obesity impacts individuals in countries worldwide and was associated with 3.7 million deaths worldwide in 2024, per the WHO.